Philips CEO Warns About 2026 Growth Target, Stock Drops

Koninklijke Philips NV (NYSE: PHG) shares fell sharply on Thursday, marking their most significant single-day drop since February.

Benzinga • Dec 4, 2025

Philips reiterates timing of 2026 outlook

December 4, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the company's previously communicated schedule. As previously guided, the company expects continued performance improvement with sequential comparable sales growth, expanded margins (despite tariff headwinds) and strong cashflow.

GlobeNewsWire • Dec 4, 2025

Polarean coil cleared for use on Philips' newest MRI scanners

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has cleared a key hurdle in its push to expand the reach of its Xenon-based lung scans, after its dedicated chest coil passed compatibility testing with Philips' latest magnetic resonance imaging systems. The company said Philips had completed its own validation of the XENOVIEW 3T Chest Coil, which was cleared by the US Food and Drug Administration last year.

Proactive Investors • Dec 1, 2025

Philips expands commercial availability of world's first real-time AI-enabled light-based 3D navigation solution for image-guided therapy

December 1, 2025 Commercial availability expanded across Europe and the United States Real-time AI-enabled 3D device visualization powered by light instead of X-ray, improving navigation in complex endovascular procedures LumiGuide seamlessly integrates with Azurion, Philips' proven, world-leading image-guided therapy platform designed to drive procedural innovation across clinical domains Amsterdam, the Netherlands and Chicago, USA – Royal Philips (NYSE: PHG, AEX: PHIA, a global leader in health technology, today announced the expanded commercial availability of LumiGuide 3D Device Guidance, the world's first real-time AI-enabled light-based 3D navigation solution for image-guided therapy, across Europe and the United States. LumiGuide represents a breakthrough in radiation-free* navigation, allowing physicians to visualize and guide devices inside the body using light instead of continuous X-ray.

GlobeNewsWire • Dec 1, 2025

XENOVIEW® 3T coil passes Philips compatibility testing

Polarean's FDA cleared coil achieves important milestone, expanding clinical reach Polarean's FDA cleared coil achieves important milestone, expanding clinical reach

GlobeNewsWire • Dec 1, 2025

Polarean shares jump 12% after Philips clears its Xenon lung-scan tech

Polarean Imaging PLC's (AIM:POLX, OTC:PLLWF) stock popped 12% to 0.14p on Monday after the company cleared a major technical hurdle in its bid to get Xenon-based lung scans into more hospitals. Philips has signed off on Polarean's XENOVIEW 3T chest coil, confirming it plays nicely with the Dutch giant's next wave of 3-tesla MRI scanners.

Proactive Investors • Dec 1, 2025

Philips unveils BlueSeal Horizon, industry's first helium-free 3.0T MRI platform

November 30, 2025 Major technology breakthrough combines advanced AI for clinical insights and accelerated workflow in new premium 3.0T MRI platform [1] Amsterdam, the Netherlands, and Chicago, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today unveiled BlueSeal Horizon [1], an entirely new 3.0T MRI innovation platform that includes the industry's first helium-free 3.0T magnet at RSNA 2025. A pivotal advance in MRI innovation, helium-free [2] 3.0T is a major scientific achievement set to have significant impact for health providers and patients.

GlobeNewsWire • Nov 30, 2025

Philips launches Verida, world's first detector-based spectral CT powered by breakthrough AI, to advance diagnostic precision

November 30, 2025 Philips pioneered detector-based spectral CT, which has been widely adopted in clinical routine exams across anatomies, supported by over 800 peer-reviewed publications [1] CE-marked, 510k pending Verida CT [2] integrates AI across the imaging chain, providing superb image quality while accelerating workflow and reducing dose [3, 4] Amsterdam, the Netherlands and Chicago, USA – At RSNA 2025, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Verida, the world's first detector-based spectral CT fully powered by AI. This marks a transformative milestone in CT, with AI optimizing the entire imaging chain – lowering system noise, elevating image quality, and accelerating clinical workflow.

GlobeNewsWire • Nov 30, 2025

Philips launches next-generation web-based diagnostic viewer for fast, secure imaging data access anywhere

November 24, 2025 New viewer offers full radiology capabilities, interfaces with AI and interactive reporting module to streamline workflows Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Philips Image Management 15, the next generation of Philips Vue PACS, including a zero-footprint, web diagnostic viewer [1] that transforms how radiologists access and interpret medical images. Designed with a brand-new user interface, the viewer delivers the full clinical power of a desktop workstation through a standard web browser.

GlobeNewsWire • Nov 24, 2025

Philips and Cortechs.ai extend partnership to advance quantitative neuroimaging and strengthen Philips' leadership in precision diagnostics in neurology

November 19, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced an extended partnership with Cortechs.ai, a pioneer in quantitative neuroimaging solutions. Together, the companies will integrate Cortechs.ai's advanced AI-enabled neuroimaging analytics directly into Philips' MR systems [1], empowering clinicians with faster, more objective, and reproducible insights into brain health. The collaboration strengthens Philips' leadership in precision neuro diagnostics, combining Philips' next-generation MR technologies with Cortechs.ai's AI-driven quantitative neuro imaging post processing software [1] to transform how neurological diseases are detected, monitored, and managed. Combining complementary expertise for smarter brain imaging Up to 25% [2] of all MR procedures are brain scans, and radiology departments face growing demand amid increasing staff shortages. At the same time, the number of patients with neurological conditions such as Alzheimer's disease, multiple sclerosis (MS), and brain tumors continue to rise globally. Current MR interpretation of neurodegenerative diseases or neuro oncology cases depends heavily on visual assessment, introducing variability and requiring significant expertise and time in an already overloaded system. Through this extended partnership, Philips and Cortechs.ai aim to deliver more standardized and data-driven imaging. By integrating quantitative analysis tools such as brain volumetrics, lesion quantification, and tumor tracking directly into the Philips MR imaging workflow [1], clinicians gain objective, numerical data alongside images – enabling faster, more consistent, and confident diagnoses. Empowering clinicians with precision and speed The integration of Cortechs.ai's NeuroQuant® solutions for Alzheimer's, MS and brain tumors within Philips' Smart Reading environment – a cloud-based AI platform that combines imaging, reading, and reporting directly on the MR systems [1] – marks a major step toward precision neuroimaging. With this integration, clinicians can automatically receive AI-generated quantitative reports within their standard MR workflow on the MR system or PACS, without adding extra steps for technologists. The zero-click process ensures quality-checked data and standardized outputs, helping radiologists interpret brain scans more objectively, faster and with greater confidence. “By extending our partnership with Cortechs.ai, we are accelerating the transition to fully quantitative, AI-powered neuroimaging,” said Ioannis Panagiotelis, PhD, Business Leader, MRI, Philips. “This integration brings precision, reproducibility, and efficiency to neurological MR, helping clinicians make faster, more confident decisions for patients living with complex brain conditions.” Driving productivity and improving care through AI Philips is driving productivity and improving care through deep AI integration that tackles some of healthcare's most pressing challenges – from workforce shortages to the growing demand for advanced diagnostics. By automatically generating quantitative reports within existing workflows, AI helps radiologists save time, improve consistency, and boost throughput. Objective numerical biomarkers enhance diagnostic accuracy, enabling more reproducible assessments and confident comparisons across time and sites. And by minimizing manual post-processing through automated, quality-controlled workflows, technologists can focus more on what matters most – delivering a better, more personalized patient experience. “Cortechs.ai's mission has always been to empower clinicians with actionable, quantitative insights,” said Kyle Frye, Chief Executive Officer, Cortechs.ai. “By combining our advanced neuro analytics with Philips' leading MR platform and AI infrastructure, we're making it easier to personalize brain care and track neurological changes with precision.” Setting a new standard in precision neuro diagnostics Cortechs.ai's  NeuroQuant® solutions are already available on Philips Advanced Visualization Workspace. With this extended partnership, Philips reinforces its commitment to advancing the field of neurology – empowering healthcare providers to deliver better care for more people, in less time, with greater confidence.

GlobeNewsWire • Nov 19, 2025